Brustzentrum
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
KLINIKUM DER UNIVERSITÄT MÜNCHEN
®
THERAPY CONCEPTS EARLY BREAST
CANCER
HER2
positive
chemotherapy
+ trastuzumab (*+
pertuzumab)
±
endocrine therapy
chemotherapy
ER
and
PR
and
HER2
negative
Low risk
High risk
Lymph node involvement (< 3 vs > 4 LK)
Grade
Tumor biology
• uPA/PAI-1
• Gene-signatures
• Ki-67
endocrine
therapy
chemotherapy
→ endocrine
therapy
ER and/or PR positive
(HER2 negative)
adapted from Harbeck, Salem, Gluz et al, 2010
preferentially neoadjuvant*
indication for chemotherapy ≥ pT1b, pN0
